Health and Fitness Health and Fitness
Mon, January 7, 2013
Sun, January 6, 2013
Fri, January 4, 2013
Thu, January 3, 2013
Wed, January 2, 2013
Mon, December 31, 2012
Fri, December 28, 2012
[ Fri, Dec 28th 2012 ] - Market Wire
Verisante Issues Stock Options
Thu, December 27, 2012
Wed, December 26, 2012
[ Wed, Dec 26th 2012 ] - Market Wire
30 p.m. ET
Mon, December 24, 2012
Fri, December 21, 2012
Thu, December 20, 2012
[ Thu, Dec 20th 2012 ] - Market Wire
A View from the Top
Wed, December 19, 2012
Tue, December 18, 2012
Mon, December 17, 2012
Fri, December 14, 2012
Thu, December 13, 2012
Wed, December 12, 2012
Tue, December 11, 2012
Mon, December 10, 2012
Sun, December 9, 2012
Sat, December 8, 2012
Fri, December 7, 2012
Thu, December 6, 2012

USPTO Grants Quick-Med Patent for Wound Dressing Utilizing Two NIMBUS(R) Formats


Published on 2012-12-19 05:01:09 - Market Wire
  Print publication without navigation


December 19, 2012 07:43 ET

USPTO Grants Quick-Med Patent for Wound Dressing Utilizing Two NIMBUS® Formats

Ninth NIMBUS Patent Covers Methods and Compositions for an Antimicrobial Bandage Combining a NIMBUS Substrate With NIMBUS SAP

GAINESVILLE, FL --(Marketwire - December 19, 2012) - Quick-Med Technologies, Inc. (OTCQB: [ QMDT ]), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that it has been awarded a ninth U.S. patent for its novel, non-leaching NIMBUS antimicrobial technology.

The U.S. Patent and Trademark Office has issued Quick-Med Technologies U.S. Patent No. 8,333,743 titled, "Antimicrobial Bandage Material Comprising Superabsorbent and Non-Superabsorbent Layers." The new patent covers the method of combining a NIMBUS-treated substrate with a NIMBUS-treated superabsorbent polymer to achieve both high capacity of fluids absorption and a high level of safe, non-leaching antimicrobial activity while maintaining the feel and handling characteristics of a conventional fabric. A major function of healthcare bandages is the absorption of wound fluids, which can provide a rich source of nutrients to drive bacterial growth. This combination of antimicrobial products allows the design of dressings with tailored fluid handling and the convenience, economy and ease of handling of traditional wound care products.

"We are very pleased that U.S. Patent Office has issued this Notice of Allowance," said Bernd Liesenfeld, Quick-Med's president. "This new patent represents an important extension of our NIMBUS technology in that it applies to a wide range of product applications in addition to wound dressings where the combination enhanced antimicrobial efficacy and high capacity fluid absorbency is desired."

About NIMBUS
Quick-Med's patented technology, NIMBUS, is a cutting-edge antimicrobial technology that has been custom designed for wound care and other medical applications. NIMBUSreceived De Novo FDA clearance in 2009 and has been commercialized in traditional wound care applications.It is the only non-leaching antimicrobial dressing which, by design, poses no risk of bacteria developing resistance. NIMBUS technology is protected by twelve U.S. patents and patents pending and 24 foreign counterparts. Additional applications under development include advanced wound dressings, medical adhesives, catheters, and contact lenses.

About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. is a life sciences company that is developing proprietary, broad-based technologies for infection prevention and control in the consumer and healthcare markets. In addition to NIMBUS, Quick-Med's Stay Fresh technology provides highly durable antimicrobial protection for laundered apparel and other textile applications and its NimbuDerma" technology is being developed as a long-lasting hand sanitizer. For more information, see: [ www.quickmedtech.com ].

2012 Quick-Med Technologies, Inc. All rights reserved. NIMBUS is a registered trademark of Quick-Med Technologies, Inc.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "expect," "plan," "believe," "anticipate," "intend," "could," "would," "estimate," and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at[ www.sec.gov ].




Publication Contributing Sources